#USA #Anixa Biosciences #San Jose #CAR-T therapy #Ovarian Cancer

Overview of CAR-T Clinical Trial Progress

Anixa Biosciences, Inc., in collaboration with the Moffitt Cancer Center, has made significant strides in their clinical trial for a CAR-T therapy focused on treating recurrent ovarian cancer. Recently, the company proudly announced the treatment of the first patient in the fifth cohort of their ongoing Phase 1 clinical trial, a critical stepping stone in their journey towards offering innovative cancer treatment solutions.

Details of the Clinical Trial

The ongoing trial, registered under ClinicalTrials.gov (NCT05316129), evaluates the safety and efficacy of a novel CAR-T therapy that targets the follicle-stimulating hormone receptor (FSHR), which is primarily found in ovarian cancer cells. This specific targeting is crucial as it minimizes potential side effects and maximizes treatment effectiveness, being expressed minimally in normal tissues.

Each patient within this trial is subjected to an escalating dose regimen designed to assess the treatment's safety and tolerability. The latest cohort involves administering 1×10⁷ CAR-positive cells per kilogram of body weight after lymphodepletion, marking the highest dose administered in this trial to date.

Outcomes Observed So Far

An encouraging development in this trial is the notable survival rate of the patients. Several participants have achieved survival times exceeding one year following their treatment. Notably, one individual has survived for over two years, which is remarkable considering the challenging prognosis typically associated with recurrent ovarian cancer, particularly for patients who have undergone multiple previous therapies with limited options remaining.

To date, the trial has reported no dose-limiting toxicities, which adds to the promising nature of the CAR-T therapy being investigated. Tackling ovarian cancer, often regarded as one of the more lethal forms of the disease affecting women, represents a compelling challenge, and the lack of observed side effects thus far is a heartening sign for both researchers and patients alike.

Insights from Leadership

Dr. Amit Kumar, Chief Executive Officer and Chairman of Anixa Biosciences, articulated the significance of advancing to the fifth cohort. He stated, “Advancing to the fifth cohort and highest dose level while observing no dose-limiting toxicities so far is a meaningful milestone for the program.” He underscored the desperate need for effective treatment options amid the obstacles faced by patients enduring recurrent ovarian cancer, which is often compounded by a history of ineffective treatments.

He further expressed hope that the emerging data from their research could lead to more practical treatment paradigms that could transform the landscape of care provided to women battling this disease.

About Anixa's CAR-T Technology

The CAR-T therapy referred to as liraltagene autoleucel, or lira-cel, utilizes a groundbreaking approach where the therapy specifically targets FSHR. This differentiation allows the treatment to effectively attack tumor cells while minimizing collateral damage to healthy tissues.

This trial, focusing on recruiting adult women with recurrent ovarian cancer who have not responded to earlier treatments, is part of Anixa's long-term plan to develop advanced treatment options in collaboration with top-tier research centers, such as the Moffitt Cancer Center.

The Road Ahead

As the Phase 1 trial progresses, Anixa aims to continue enrolling patients and monitoring results closely. The expectation is that the research will not only elucidate the safety and efficacy of this CAR-T approach but also inspire future innovations in cancer immunotherapy.

The journey ahead is filled with possibilities, and Anixa remains committed to transforming the treatment landscape for ovarian cancer through persistent research and clinical exploration. By staying at the forefront of cancer treatment, Anixa Biosciences is making strides toward a future where innovative therapies can significantly enhance patient outcomes across multiple cancer types.

For more information on Anixa's ongoing work, please visit Anixa's website.